UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

File	Filed by the Registrant ⊠						
File	Filed by a Party other than the Registrant □						
Che	Check the appropriate box:						
	Preliminary Proxy Statement						
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))						
	Definitive Proxy Statement						
\boxtimes	Definitive Additional Materials						
	Soliciting Material Pursuant to §240.14a-12						
	APELLIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)						
	(Name of person(s) filing proxy statement, if other than the registrant)						
Pay	Payment of Filing Fee (Check the appropriate box):						
\boxtimes	No fee required.						
	Fee paid previously with preliminary materials.						
	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.						
Acti	iveUS 198349307v.10						

Apellis

P.D. BOX 80%, CARY, NC 27512-9903

YOUR VOTE IS IMPORTANT! PLEASE VOTE BY:



- Go To: www.proxypush.com/APLS
- Cast your vote online
 Have your Proxy Card ready
- . Follow the simple instructions to record your vote



PHONE Call 1-866-362-4346

- . Use any touch-tone telephone
- Have your Proxy Card ready
 Follow the simple recorded instructions

INTERNET

- Mark, sign and date your Proxy Card
 Fold and return your Proxy Fold and return your Proxy Card in the postage-paid envelope provided



You must register to attend the meeting online and/or participate at www.proxydocs.com/APLS

Apellis Pharmaceuticals, Inc.

Annual Meeting of Stockholders

For Stockholders of record as of April 03, 2023

Thursday, June 1, 2023 10:00 AM, Eastern Time TIME:

PLACE: Annual Meeting to be held live via the internet - Please visit

www.proxydocs.com/APLS for more details.

This proxy is being solicited on behalf of the Board of Directors

The undersigned hereby appoints Cedric Francois, Timothy Sullivan and David Watson, and each of them, as the true and lawful attorneys of the The undersigned nereby appoints cearce Prancois, I imothly Sullivan and David Watson, and each of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of capital stock of Apellis Pharmaceuticals, Inc. which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given.

THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof.

You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors' recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card.

Apellis Pharmaceuticals, Inc.

Annual Meeting of Stockholders

Please make your marks like this: X

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE NOMINEES IN PROPOSAL 1 AND FOR PROPOSALS 2 AND 3

	PROPOSAL		YOUR VOTE		BOARD OF DIRECTORS RECOMMEND
1.	To elect two Class III directors to hold office until the 2026 annual meeting of stockholders.				
	1.01 Gerald Chan	FOR	WITHHOLD		FOR
	1.02 Cedric François				FOR
2.	To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	FOR	AGAINST	ABSTAIN	FOR
3.	To approve an advisory vote on executive compensation.				FOR

You must register to attend the meeting online and/or participate at www.proxydocs.com/APLS

Authorized Signatures - Must be completed for your instructions to be executed.

Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form.



P.O. BOX 8016, CARY, NC 27512-9903

Apellis Pharmaceuticals, Inc. Important Notice Regarding the Availability of Proxy Materials

Stockholders Meeting to be held on June 1, 2023

For Stockholders of record as of April 03, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/APLS

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/APLS

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.



If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 22, 2023.

To order paper materials, use one of the following methods.



INTERNET

www.investorelections.com/APLS

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.



* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

Apellis Pharmaceuticals, Inc.

Meeting Type: Annual Meeting of Stockholders **Date:** Thursday, June 1, 2023

Time: 10:00 AM, Eastern Time

Place: Annual Meeting to be held live via the internet - Please visit

www.proxydocs.com/APLS for more details

You must register to attend the meeting online and/or participate at www.proxydocs.com/APLS

SEE REVERSE FOR FULL AGENDA

Apellis Pharmaceuticals, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE ${f FOR}$ EACH OF THE NOMINEES IN PROPOSAL 1 AND ${f FOR}$ PROPOSALS 2 AND 3

PROPOSAL

- 1. To elect two Class III directors to hold office until the 2026 annual meeting of stockholders.
 - 1.01 Gerald Chan
 - 1.02 Cedric Francois
- To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
- 3. To approve an advisory vote on executive compensation.